VIP943

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies

Near Add Your Location

Sorting 5 by

Sarah Cannon Research Institute at Tennessee Oncology
TriStar Centennial Medical Center
Nashville, TN
  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients

Center of Excellence

University of Cincinnati College of Medicine
George L. Strike Bone Marrow Transplant Program
Cincinnati, OH
  • Accepting patients

Center of Excellence

Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
  • Accepting patients
519 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.